BioCryst Pharmaceuticals | Koszty Operacyjne





Koszty Operacyjne Zmiana Data
Alnylam Pharmaceuticals USD 965.32M 84.27M 2025-12
BioCryst Pharmaceuticals USD -387.89M 33.7M 2025-09
Chugai Pharma JPY 177.3B 604M 2025-12
Daiichi Sankyo JPY 468.57B 15.34B 2025-12
DBV Technologies USD 37.05M 4.06M 2025-09
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 7.18B 1.42B 2025-12
Glaxosmithkline GBP 7.77B 2.22B 2025-09
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 418M 101.1M 2025-12
Karyopharm Therapeutics USD 61.82M 3.24M 2024-12
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novavax USD 218.53M 34.86M 2024-09
PTC Therapeutics USD 246.3M 38.78M 2025-12
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Ultragenyx Pharmaceutical USD 321M 9.82M 2025-12
Vertex Pharmaceuticals USD 1.93B 89.1M 2025-12


BioCryst Pharmaceuticals Koszty Operacyjne - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2026.